- Home
- MCRB vs FORR Comparison
MCRB vs FORR Comparison
Compare MCRB & FORR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRB | FORR |
|---|---|---|
| Founded | 2010 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.7M | 154.9M |
| IPO Year | 2015 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MCRB | FORR |
|---|---|---|
| Price | $15.92 | $8.32 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $14.33 | N/A |
| AVG Volume (30 Days) | 60.6K | ★ 97.7K |
| Earning Date | 11-05-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | $351,000.00 | ★ $403,871,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.79 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.53 | $6.60 |
| 52 Week High | $29.98 | $15.80 |
Technical Indicators
Market Signals| Indicator | MCRB | FORR |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 67.15 |
| Support Level | $14.90 | $8.09 |
| Resistance Level | $16.00 | $8.44 |
| Average True Range (ATR) | 0.77 | 0.29 |
| MACD | 0.20 | 0.06 |
| Stochastic Oscillator | 82.78 | 90.17 |
Price Performance
Historical ComparisonAbout MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.